Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.
Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.
The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.
Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.
For the latest updates and more information, visit Stereotaxis.
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that David Fischel, Chairman and CEO, will participate in TD Cowen's 45th Annual Healthcare Conference in Boston, Massachusetts. Mr. Fischel will present an overview of Stereotaxis on Monday, March 3rd, 2025, at 3:10 pm ET and will be available for one-on-one meetings that same day.
Stereotaxis is focused on the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. Their innovations help physicians provide patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance productivity in operating rooms. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its fourth quarter and full year 2024 financial results release for March 3, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET the same day.
Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 1983976. A webcast will be available through the investor relations section of Stereotaxis' website, and a phone replay will be accessible for one month after the call.
The company's technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.
Stereotaxis (NYSE: STXS) has received its first order for the GenesisX™ robotic system from a European hospital. GenesisX represents the latest advancement in endovascular surgical robotics, featuring smaller magnets and built-in magnetic shielding, eliminating the need for wall shielding installation.
The system operates on standard power outlets without requiring structural floor anchoring. It includes a cabinet 80% smaller than previous versions and can be stored under an operating room table. The system maintains high performance standards while being more compact and lighter than previous generations.
GenesisX received CE Mark in Europe in 2024 and is pending FDA 510(k) clearance in the US. Throughout 2025, Stereotaxis plans to obtain regulatory approvals for compatible catheters, demonstrate real-world usage, enhance x-ray compatibility, and prepare for full commercial launch.
Stereotaxis (NYSE: STXS) has received European CE Mark approval for its MAGiC™ ablation catheter, designed for cardiac ablation procedures treating heart arrhythmia. The catheter was developed based on insights from nearly 20 years and 150,000 robotic ablation procedures using predecessor devices.
The MAGiC catheter features enhanced capabilities including optimized navigation with consistent contact forces, improved data collection through iConnect and eContact module integration, and efficient low-flow cooling that reduces patient fluid load. The device received broad European approval for creating local lesions in cardiac tissue to treat cardiac arrhythmias.
This approval follows extensive development, testing, manufacturing, and clinical research investments. Clinical studies in Europe support expectations for widespread adoption among robotic users.
Stereotaxis (NYSE: STXS) announced that Oulu University Hospital in Finland has successfully implemented and begun treating patients with the advanced Genesis Robotic Magnetic Navigation (RMN) System. The hospital, which has previously treated over 2,000 patients with earlier versions of the technology, is now enhancing its arrhythmia care capabilities in northern Finland.
The Genesis System represents a significant advancement in Robotic Magnetic Navigation technology for cardiac ablation procedures, offering robotic precision and safety in treating arrhythmias. This condition, affecting tens of millions globally, can lead to increased risks of stroke, heart failure, and sudden cardiac arrest if left untreated.
Dr. Jarkko Magga, Cardiac Electrophysiologist at Oulu University, highlighted that robotic technology has been important to their team's ability to provide superior care for complex cardiac arrhythmias over the past 15 years. The hospital's adoption of the Genesis System demonstrates their commitment to maintaining high-quality patient care standards.
Stereotaxis (NYSE: STXS) and MicroPort EP announced that China's NMPA has approved the Magbot™ Magnetic Navigation Ablation Catheter. This single-use magnetic saline-irrigated radiofrequency ablation catheter works exclusively with Stereotaxis' robotic systems and MicroPort EP's Columbus™ 3D EP Mapping System.
The Magbot™ features advanced design elements including a unique six-electrode configuration for enhanced safety and reduced fluoroscopy needs. It's approved for treating drug-resistant persistent atrial fibrillation and other cardiac conditions. The catheter enables precise positioning with millimeter-level accuracy using low-intensity magnetic fields.
MicroPort EP will handle the commercial launch in China through its existing sales team, with Stereotaxis sharing in the proceeds from Magbot™ adoption.
Stereotaxis (NYSE: STXS) announced that its latest GenesisX robotic system is being featured at Neusoft Medical Systems' booth during RSNA 2024, the world's premier radiology forum in Chicago. The system is being showcased alongside Neusoft's NeuAngio 30F fluoroscopy system, marking a growing collaboration between the companies to integrate and commercialize complementary technologies.
GenesisX builds upon Robotic Magnetic Navigation technology, aiming to enhance precision, efficiency, and safety in endovascular procedures while reducing hospital adoption barriers. The event, attended by over 50,000 professionals from 150+ countries, represents the first public showcase of the GenesisX system.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announces its participation in the Piper Sandler 36th Annual Healthcare Conference. Chairman and CEO David Fischel will present the company's technology and growth strategy on December 5, 2024, at 2:00 pm ET, and will be available for one-on-one meetings.
The company's innovative robotics technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis focuses on developing robotic systems, instruments, and information solutions for the interventional laboratory, aiming to enhance physician care delivery with robotic precision and safety.
Stereotaxis (NYSE: STXS) and MicroPort EP announced that China's National Medical Products Administration (NMPA) has approved the Genesis RMN® System. This approval enables the commercialization of advanced robotic technology for minimally-invasive procedures in China. MicroPort EP will lead the commercial launch through its existing electrophysiology sales teams. The approval is part of a broader collaboration between both companies, announced in August 2021, which includes development and integration of robotic systems, navigated catheters, and MicroPort EP's Columbus™ 3D mapping system. The Genesis system, already FDA-cleared and CE-marked, has been used to treat thousands of patients in the US and Europe.
Stereotaxis (NYSE: STXS) announced that Hospital da Luz in Lisbon, Portugal has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. Hospital da Luz Lisboa, part of Portugal's largest health group Luz Saude, is a university hospital that has performed over 4,000 robotic cardiac ablation procedures. The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through minimally invasive cardiac ablation procedures with robotic precision and safety.
FAQ
What is the current stock price of Stereotaxis Ord (STXS)?
What is the market cap of Stereotaxis Ord (STXS)?
What does Stereotaxis, Inc. specialize in?
What is the mission of Stereotaxis, Inc.?
Where has Stereotaxis' technology received regulatory clearance?
What are the main revenue streams for Stereotaxis, Inc.?
Who are the key executives at Stereotaxis, Inc.?
How does Stereotaxis' technology benefit physicians?
How many patents does Stereotaxis hold?
What geographic region generates the majority of Stereotaxis' revenue?
What types of procedures are enhanced by Stereotaxis' technology?
Where can I find more information about Stereotaxis, Inc.?
